Global Brain Tumor Drugs Market (2022 to 2031) – Featuring Pfizer, Shimadzu and Celgene Among Others – ResearchAndMarkets.com – Yahoo Finance

Number of claims falls to the lowest level since 1968
DUBLIN, April 07, 2022–(BUSINESS WIRE)–The "Brain Tumor Drugs Global Market Report 2022, Type, Drugs, End User" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global brain tumor drugs market as it emerges from the COVID-19 shut down.
The global brain tumor drugs market is expected to grow from $3.17 billion in 2021 to $3.49 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.84 billion in 2026 at a CAGR of 8.5%.
Companies Mentioned
Pfizer Inc.
Shimadzu Corporation
Toshiba Medical Systems
Merck & Co. Inc.
AstraZeneca
Carestream Health
Philips Healthcare
Siemens Healthineers
Hitachi Medical Corporation
GE Healthcare
Novartis AG
Bristol-Myers Squibb
AbbVie
Astellas Pharma
Roche
Celgene
Johnson & Johnson
Genetech U.S.A
Hoffmann- La Roche
Antisense Pharma
Macleods Pharmaceutical Limited
Mankind Pharma
Dr. Reddys Laboratories Ltd.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and locations of the tumor.
The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib. Temozolomide is a drug that is intended to treat some types of brain cancer (e.g., glioblastoma multiforme, anaplastic astrocytoma) in individuals who have had tumours return or who have recently been diagnosed with tumours. It's one of a class of drugs called as antineoplastics (cancer medicines). The different types include medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), others (glioma, acoustic neuroma, meningioma) and is used in various sectors such as hospital pharmacies, clinics and others.
North America is the largest region in the brain tumor drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections and sedentary lifestyle. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having primary brain tumor in 2019 and around 86,000more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor, is leading to a rise in the demand for the drugs used in their treatment.
Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. For example, Everolimus is a targeted therapy that specially blocks the cancer cells from growing and spreading. Similarly, Bevacizumab prevents regeneration of cancer cells unlike chemical drugs which cannot prevent regeneration. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, thus restraining the growth of the market during the forecast period.
For more information about this report visit https://www.researchandmarkets.com/r/5m22xy
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005563/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
The pharma company is testing a vaccine for respiratory syncytial virus. Thursday's deal gives it an antiviral treatment in Phase 2 testing.
The FDA has approved BioXcel Therapeutics Inc's (NASDAQ: BTAI) Igalmi (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Igalmi can be self-administrated by patients under the supervision of a healthcare provider. The company is prepared to launch Igalmi in the U.S. in Q2 of 2022. An estimated 7.3 million people in the U.S. are diagnosed with schizophrenia or bipolar disorders. Up to a quarter of these peopl
Retail titan Costco Wholesale reported that comparable sales surged 12% in March from a year earlier, excluding the impact of gasoline prices and foreign exchange. Costco's net sales rose 17% to $130 billion in the first 31 weeks of the company's current fiscal year compared with a year ago. As of March 31, Costco had 829 warehouse locations, up 2.7% from 807 a year earlier.
Tesla (NASDAQ: TSLA) stock galloped out of the gate Thursday morning — up 2.3% as of 10:25 a.m. ET before falling back around midday — as the company announced a "Cyber Rodeo" to celebrate the opening of its Austin, Texas, Gigafactory barely two weeks after opening a Gigafactory in Germany. It's starting to get hard to remember all the places Tesla now has Gigafactories up and running. The Austin Gigafactory will initially produce Model Y electric vehicles, and thus contribute to Tesla's goal of building 1.5 million or more EVs this year.
Vaccine stocks toppled Wednesday after an Israeli study suggested immunity wanes quickly following a second Covid booster shot.
After two messy, drama-filled weeks struggling to fill the top job at state-run oil company Petrobras Brazil's government turned this week to low-profile technocrat José Mauro Coelho, and investors welcomed the move. Coelho's record indicates he is not keen on sacrificing Petrobras profits to keep fuel prices low for Brazilian drivers, or to accomplish other policy aims. Last week, energy consultant Adriano Pires backed out of the government's nomination to take the helm at Petrobras, shortly after soccer magnate Rodolfo Landim declined a nomination as chairman.
(Bloomberg) — Tankers carrying 22 million barrels of Russian, Iranian and Venezuelan oil are piling up off China, according to Kpler, as the country battles a virus outbreak that’s sapping demand and causing logistics problems.Most Read from BloombergCanada to Ban Foreigners From Buying Homes as Prices SoarMocked as ‘Rubble’ by Biden, Russia’s Ruble Roars BackUkraine Update: UN to Vote on Dropping Russia From Rights BodyRussia Skirts Nearer Default After Dollar Payment BlockedIndia to Face Sign
Shares of Aptinyx Inc. tumbled 48.7% in premarket trading on Thursday after the company said an experimental treatment for painful diabetic peripheral neuropathy failed to meet the primary endpoint in a Phase 2b clinical trial. "The data from this study do not currently point to a path forward in development for painful DPN," Aptinyx CEO Andy Kidd said in a news release. The company said it is still evaluating the therapy as a treatment for fibromyalgia, and data is expected from a Phase 2b stud
Since the end of the Great Recession 13 years ago, growth stocks have dominated. According to consensus revenue estimates from Wall Street, the following three companies should be among the fastest-growing stocks on the planet through 2026. Perhaps it's no surprise that one of the hottest initial public offerings of 2021, electric-vehicle (EV) manufacturer Rivian Automotive (NASDAQ: RIVN), is expected to be one of the stock market's fastest-growing stocks over the next five years.
There is another event happening in Austin that is also big deal for the stock, even though the impact isn't as direct as a new manufacturing facility: Tesla-Con.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ: HOWL) WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule. "We believe WTX-613 has the potential to minimize the toxicity associated with systemic IFNα therapy, preferentially delivering IFNα to tumors, and thereby expanding its clinical utility in treating cancer," said Rob Iannone, executive vi
Previously, the United States had identified more than 170 Boeing airplanes that Russian airlines were operating in violation of U.S. sanctions, including about 40 Aeroflot Boeing 737 and 777 airplanes, 21 Azur Boeing planes and 17 UTair Boeing aircraft. Deputy Commerce Secretary Don Graves said the message was clear: "Defy our export controls at your own peril."
Oil executives on Capitol Hill defended their companies as Democratic lawmakers accused them of price gauging during a hearing hosted by the House Committee on Energy & Commerce.
Iovance hinted at a one-quarter delay for its melanoma treatment this week, but IOVA stock continued a two-day recovery Thursday.
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has consummated a contract with the Toronto Institute of Pharmaceutical Technology (TIPT®) to formulate and manufacture psilocybin microdose capsules for its upcoming Canadian Phase 2A fragile X syndrome ("FXS") clinical
Pharmaceutical company Pfizer (NYSE: PFE) saw its shares rise 10.3% in March according to data from S&P Global Market Intelligence. Pfizer's move didn't stem from one announcement, but rather was a steady rise based on several developments. The biggest news for Pfizer in March was that the Food and Drug Administration (FDA) had expanded the Emergency Use Authorization for Pfizer's COVID-19 vaccine to be used as a second booster shot.
Pioneer Natural Resources is an independent oil and gas exploration and production company and like many stocks in the energy sector, its charts are pointed higher. In this daily bar chart of PXD, below, we can see that prices have rallied the past 12 months. The On-Balance-Volume (OBV) line shows strength from early September with buyers of PXD being more aggressive than sellers with heavier volume being transacted on days when PXD has closed higher.
Use this airfare saving tip, says one Wall Street analyst who covers the industry.
With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.
Oil executives told lawmakers on Wednesday they can't take away the pain consumers are feeling at the pump.

source

Add a Comment

Your email address will not be published. Required fields are marked *